Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 3/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056493 | 1.00 | ALDH1A1 (0.48) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL6056463 | 0.94 | FNTA (0.55) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL6056453 | 0.94 | FNTA (0.55) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL6056393 | 0.83 | TDP1 (0.69) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL8366056 | 0.81 | REN (0.48) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL6056396 | 0.80 | EGFR (0.46) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8075746 | 0.80 | ALDH1A1 (0.49) | ALDH1A1EGFRFYNCHRM2CYP3A4 | |
| SCHEMBL7624701 | 0.79 | FNTA (0.52) | ALDH1A1FNTBFNTA | |
| SCHEMBL7624707 | 0.79 | FNTA (0.52) | ALDH1A1FNTBFNTA | |
| SCHEMBL6056468 | 0.78 | EGFR (0.46) | ALDH1A1EGFRFYNCHRM2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | claimed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | claimed |
| WO-2006017369-A2 | USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | CAMPOCHIARO PETER A (US) | 2002-01-17 | — | — | US | disclosed |
| US-6160015-A | ADMINISTERING TO MAMMAL A FARNESYL PROTEIN TRANSFERASE INHIBITOR | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0840605-A4 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIV CINCINNATI (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998057654-A1 | METHODS FOR TREATMENT OF OCULAR NEOVASCULARIZATION | JOHNS HOPKINS UNIVERSITY (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0840605-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | University of Cincinnati (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997002817-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIVERSITY OF CINCINNATI (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5576293-A | TETRAPEPTIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | GGT1, FNTA, PIGO | ALDH1A1 679/4885EGFR 3298/4885FYN 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.